4-[(1,3-dioxoisoindolin-2-yl)methyl]benzenesulfonyl chloride | 402925-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4-[(1,3-dioxoisoindolin-2-yl)methyl]benzenesulfonyl chloride
• 英文别名: 4-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)benzenesulfonylchloride；4-[(1,3-dioxoisoindol-2-yl)methyl]benzenesulfonyl chloride
• CAS: 402925-20-6
• 化学式: C₁₅H₁₀ClNO₄S
• 分子量: 335.768
• InChiKey: YRTKQKYYOCBYAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  79.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(1,3-dioxoisoindolin-2-yl)methyl]benzenesulfonyl chloride 在 氨 、 水 作用下， 生成 4-phthalimidomethyl-benzenesulfonamide
  参考文献：
  名称：

  Kominato, Kumamoto Medical Journal, 1954, vol. 6, p. 139,140

  摘要：

  DOI：
• 作为产物：
  描述：

  苯酐 在 氯磺酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 4-[(1,3-dioxoisoindolin-2-yl)methyl]benzenesulfonyl chloride
  参考文献：
  名称：

  Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones

  摘要：

  In this study a series of sulphonamides and sulphonyl hydrazones of maleimide, naphthalimide and phthalimide derivatives was synthesized. The antidepressant effect of these compounds was evaluated by the forced-swimming test in mice. The behavioural parameter observed in this test is a reduction in the immobility time, which is indicative of antidepressant activity. All compounds, except 8, 11 and 24, were active as antidepressants. The most active compound was the sulphonyl-hydrazone 10 which showed an activity of around 72.02% at 60 mg/kg, it thus being more active than imipramine (10 mg/kg, ip), a commercial antidepressant. Other important results were obtained for the benzylnaphthalimide derivatives, the sulphonamides 21 and 22 showing activity of 64% at 10 mg/kg, also being more active than imipramine. These results indicate that the sulphonamides and sulphonyl-hydrazone cyclic imide derivatives are potential compounds for use in the designing of new candidates for the treatment of depression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.05.056

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20150239875A1

  公开（公告）日：2015-08-27

  Substituted 2-pyridones and pyrazinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection and oncological diseases.

  公式1中的2-吡啶酮和吡嗪酮及其用作中性粒细胞弹性蛋白酶活性抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥和肿瘤性疾病的方法。
• Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20020035137A1

  公开（公告）日：2002-03-21

  Compounds of formula (I) 1 or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP 1 B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  式（I）的化合物或其治疗上可接受的盐是蛋白酪氨酸激酶PTP1B的抑制剂。公开了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057926A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及式1的取代4-吡啶酮及其用作中性粒细胞弹性蛋白酶活性抑制剂的药物组合物，以及使用这些药物作为治疗和/或预防肺部、胃肠道和泌尿生殖系统疾病、皮肤和眼睛炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药物的方法。
• [EN] ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS<br/>[FR] DÉRIVÉS DE CARBOXAMIDINE DE PYRAZOLINE ARYLSULFONYLIQUE FORMANT DES ANTAGONISTES DE 5-HT6
  申请人：SOLVAY PHARM BV

  公开号：WO2009115515A1

  公开（公告）日：2009-09-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5- HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  这项发明涉及芳基磺酰基吡唑啉羧酰胺衍生物作为5-HT6受体拮抗剂，以及用于制备这些化合物的方法和用于它们合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以达到在帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫性障碍、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、暴食症、暴食症、恐慌发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒除可卡因、乙醇、尼古丁或苯二氮卓类药物滥用、疼痛、与脊柱损伤或头部损伤相关的障碍、脑积水、功能性肠道障碍、肠易激综合征、肥胖和2型糖尿病中的治疗效果方面的应用。这些化合物具有一般公式（1），其中符号的含义如描述中所示。